Camrelizumab

Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma

Promising Early Antitumor Activity of Camrelizumab Plus Famitinib in Advanced Melanoma

SG Tylor

A Phase II trial presented at the 2023 ASCO Annual Meeting showed that combining the PD-L1 inhibitor camrelizumab with the ...